Skip to main content
. 2023 Jun 22;24(13):10484. doi: 10.3390/ijms241310484

Figure 1.

Figure 1

Representative experimental protocol. Primary human fibroblasts, at confluence (D0), exposed to 1 ng/mL of IL-1β as an inflammatory inducer. (A) Short-time experiment (3 days), treatment with MIM-1, MIM-2, MIM-3, MIM-4, MIM-5, or vehicle (Veh.) from day 0 (D0) to day 3 (D3). Cytotoxicity, PGE2, MMP-1, and TIMP-1 levels analyzed at D3. (B) Long-time experiment (24 days) treatment with MIM-seq (10 capsules), or the Veh. Collagen deposition, PGE2, MMP-1, and TIMP-1 levels analyzed at day 24. (C) 3D gingival tissue equivalent (GTE) experiment (10 days) treatment with MIM-seq (sequence of 10 capsules), or the Veh. Histology and immunohistochemistry staining, IL-1α, PGE2, IL-6, MMP-1, and TIMP-1 levels were analyzed at day 10.